Abstract
Manufactured tobacco contains over 4, 000 toxic substances, but only a few exert adverse cardiovascular effects. Nicotine and its metabolites, carbon monoxide, thiocyanate and some aromatic amines play a strong, although different, role to determine cardiovascular damage. Of these substances, however, nicotine, acting by the double mechanism of addiction and receptor-binding, and carbon monoxide by increasing the production of carboxyhemoglobin and hypoxia, are the main determinants of the damage.
The development of the alterations of heart and blood vessels follows a typical way, initially consisting of functional responses that become irreversible pathological lesions at the time.
Myocardium and endothelial cells are the targets where cigarette smoking exerts its effects. The first displays functional and pathological disorders primarily related to ischemic heart disease, cardiomyopathy, including experimental cardiomyopathy from smoking, and heart failure, while the second should be interpreted as a structure, which shows early alterations caused by smoking as clearly evident, repeatable and typically depending on smoking toxicity.
Cardiovascular damage has a functional onset, which, at the time, leads to irreversible morphological damage of myocardial and endothelial cells.
Keywords: Tobacco toxics, myocardium, endothelium, functional damage, cell damage.
Current Pharmaceutical Design
Title:Toxics of Tobacco Smoke and Cardiovascular System: From Functional to Cellular Damage
Volume: 21 Issue: 30
Author(s): Aurelio Leone
Affiliation:
Keywords: Tobacco toxics, myocardium, endothelium, functional damage, cell damage.
Abstract: Manufactured tobacco contains over 4, 000 toxic substances, but only a few exert adverse cardiovascular effects. Nicotine and its metabolites, carbon monoxide, thiocyanate and some aromatic amines play a strong, although different, role to determine cardiovascular damage. Of these substances, however, nicotine, acting by the double mechanism of addiction and receptor-binding, and carbon monoxide by increasing the production of carboxyhemoglobin and hypoxia, are the main determinants of the damage.
The development of the alterations of heart and blood vessels follows a typical way, initially consisting of functional responses that become irreversible pathological lesions at the time.
Myocardium and endothelial cells are the targets where cigarette smoking exerts its effects. The first displays functional and pathological disorders primarily related to ischemic heart disease, cardiomyopathy, including experimental cardiomyopathy from smoking, and heart failure, while the second should be interpreted as a structure, which shows early alterations caused by smoking as clearly evident, repeatable and typically depending on smoking toxicity.
Cardiovascular damage has a functional onset, which, at the time, leads to irreversible morphological damage of myocardial and endothelial cells.
Export Options
About this article
Cite this article as:
Leone Aurelio, Toxics of Tobacco Smoke and Cardiovascular System: From Functional to Cellular Damage, Current Pharmaceutical Design 2015; 21 (30) . https://dx.doi.org/10.2174/1381612821666150803145149
DOI https://dx.doi.org/10.2174/1381612821666150803145149 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Fluoxetine and all other SSRIs are 5-HT<sub>2B</sub> Agonists - Importance for their Therapeutic Effects
Current Neuropharmacology Advances in Chagas Disease Chemotherapy
Anti-Infective Agents in Medicinal Chemistry Mechanisms Explaining the Influence of Subclinical Hypothyroidism on the Onset and Progression of Chronic Heart Failure
Endocrine, Metabolic & Immune Disorders - Drug Targets ErbB4 and its Isoforms: Patentable Drug Targets?
Recent Patents on DNA & Gene Sequences Targeting Mitochondrial Dysfunction in Chronic Heart Failure: Current Evidence and Potential Approaches
Current Pharmaceutical Design Alteration of the Beta-Adrenergic Signaling Pathway in Human Heart Failure
Current Pharmaceutical Biotechnology Role of Pharmacotherapy in Cardiac Ion Channelopathies
Current Vascular Pharmacology Inflammation and Chronic Heart Failure: From Biomarkers to Novel Anti-inflammatory Therapeutic Strategies
Medicinal Chemistry Aldosterone, From (Patho)Physiology to Treatment in Cardiovascular and Renal Damage
Current Vascular Pharmacology Role of Drug Metabolism in the Cytotoxicity and Clinical Efficacy of Anthracyclines
Current Drug Metabolism ABCC6 as a Target in Pseudoxanthoma Elasticum
Current Drug Targets Postponing Motherhood: A Demographic and Contemporary Issue
Current Women`s Health Reviews ADAM17 as a Therapeutic Target in Multiple Diseases
Current Pharmaceutical Design Monoamine Receptors in the Regulation of Feeding Behaviour and Energy Balance
CNS & Neurological Disorders - Drug Targets Highly Active Antiretroviral Therapy and Cardiovascular Complications in HIV-Infected Patients
Current Pharmaceutical Design Antithrombotic Therapy in Cardiac Embolism
Current Cardiology Reviews The Role of Endothelial Dysfunction in Aortic Aneurysms
Current Pharmaceutical Design Cardioprotection by Targeting the Pool of Resident and Extracardiac Progenitors
Current Drug Targets Inhibition of the Calcineurin-NFAT Signalling Cascade in the Treatment of Heart Failure
Recent Patents on Cardiovascular Drug Discovery Redox Processes in Neurodegenerative Disease Involving Reactive Oxygen Species
Current Neuropharmacology